Aligos Therapeutics, Inc. (ALGS)
Market Cap | 47.88M |
Revenue (ttm) | n/a |
Net Income (ttm) | -96.05M |
Shares Out | 42.94M |
EPS (ttm) | -2.25 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 44,056 |
Open | 1.14 |
Previous Close | 1.11 |
Day's Range | 1.06 - 1.19 |
52-Week Range | 0.84 - 2.41 |
Beta | 2.50 |
Analysts | Buy |
Price Target | 4.08 (+265.92%) |
Earnings Date | May 2, 2023 |
About ALGS
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secreti... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ALGS stock is "Buy." The 12-month stock price forecast is $4.08, which is an increase of 265.92% from the latest price.
News

Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...

Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -4.08% and 26.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the ...

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...

Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address ...

Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address ...

Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024
– Pipeline reprioritization emphasizes NASH and COVID-19 assets, ALG-055009 and ALG-097558, plus key ongoing collaborations, including the Merck & Co. (MSD) programs in NASH – – Overall workforce redu...

Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
– Final cohort of Phase 1 study projected to be complete in H1 2023 –

Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
Single and multiple ascending doses to be evaluated in CHB subjects throughout 2023 Single and multiple ascending doses to be evaluated in CHB subjects throughout 2023

Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD's The Liver Meeting® 2022
ALG-055009, a THR-β agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a favorable pharmacokinetic profile in subje...

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address ...

Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD's The Liver Meeting® 2022
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address ...

Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeut...

Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute's 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
Aligos' pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023 Aligos' pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2...

Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
Single ascending doses to be evaluated in healthy volunteers in Q4 2022

Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address ...

Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u...

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address u...

Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...

Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1b ASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1 st cohort fully enrolled siRNA (AL...

Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...

Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS
New York, New York--(Newsfile Corp. - February 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Aligos Therapeutics, Inc. ("Aligos" or the "Company") (NASDAQ: ALGS). Such inv...

SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders
SAN DIEGO--(BUSINESS WIRE)---- $ALGS #investigation--Aligos Therapeutics, Inc. (ALGS) Halted Development of its Lead Drug Candidate

Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)
Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete